Portfolio company Ascend Advanced Therapies acquired Florida-based GMP manufacturing capacity from Beacon Therapeutics, expanding gene therapy production.
APR 9, 2024
Contract development and manufacturing organization (CDMO) supporting advanced therapy developers from research through commercialization
Contract development and manufacturing organization (CDMO) supporting advanced therapy developers from research through commercialization. Provides process and analytical development, GMP viral-vector production, aseptic fill-finish, and GMP quality-control testing for gene therapies, immunotherapies, oncolytics, and vaccines. Since late 2024, Ascend has been aligned with ABL, Inc., with US and European locations.